These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 16221871

  • 41. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms.
    Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL.
    Eur J Immunol; 2007 Dec; 37(12):3582-6. PubMed ID: 18034431
    [Abstract] [Full Text] [Related]

  • 42. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, Tiede A, Jacob U, Schmidt RE, Witte T.
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [Abstract] [Full Text] [Related]

  • 43. Alleviation of renal disease and lymphadenopathy in MRL-Fasp(lrcg)/Fas(lprcg) (MR-lpr(cg)) mice neonatally infected with mouse mammary tumor virus encoding superantigen strongly reactive with TCR Vbeta8.2 element.
    Matsuzawa A, Yasuda T, Zhang Y, Nagase H, Yoshimoto T, Kimura M, Tsubura A.
    Viral Immunol; 2000 Feb; 13(3):297-311. PubMed ID: 11016595
    [Abstract] [Full Text] [Related]

  • 44. Genetic susceptibility to polyI:C-induced IFNalpha/beta-dependent accelerated disease in lupus-prone mice.
    Jørgensen TN, Thurman J, Izui S, Falta MT, Metzger TE, Flannery SA, Kappler J, Marrack P, Kotzin BL.
    Genes Immun; 2006 Oct; 7(7):555-67. PubMed ID: 16900204
    [Abstract] [Full Text] [Related]

  • 45. Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice.
    Kulkarni OP, Ryu M, Kantner C, Sárdy M, Naylor D, Lambert D, Brown R, Anders HJ.
    Nephrol Dial Transplant; 2012 Apr; 27(4):1358-67. PubMed ID: 21987536
    [Abstract] [Full Text] [Related]

  • 46. [Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].
    Zhai ZF, Zhou CL, Zhong BY, Ao JH, Hao F.
    Zhonghua Yi Xue Za Zhi; 2008 Feb 05; 88(6):406-10. PubMed ID: 18581896
    [Abstract] [Full Text] [Related]

  • 47. G-rich DNA suppresses systemic lupus.
    Patole PS, Zecher D, Pawar RD, Gröne HJ, Schlöndorff D, Anders HJ.
    J Am Soc Nephrol; 2005 Nov 05; 16(11):3273-80. PubMed ID: 16176997
    [Abstract] [Full Text] [Related]

  • 48. Inhibition of (S)-armepavine from Nelumbo nucifera on autoimmune disease of MRL/MpJ-lpr/lpr mice.
    Liu CP, Tsai WJ, Shen CC, Lin YL, Liao JF, Chen CF, Kuo YC.
    Eur J Pharmacol; 2006 Feb 15; 531(1-3):270-9. PubMed ID: 16413531
    [Abstract] [Full Text] [Related]

  • 49. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice.
    Inoue A, Hasegawa H, Kohno M, Ito MR, Terada M, Imai T, Yoshie O, Nose M, Fujita S.
    Arthritis Rheum; 2005 May 15; 52(5):1522-33. PubMed ID: 15880599
    [Abstract] [Full Text] [Related]

  • 50. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis.
    Quezada SA, Eckert M, Adeyi OA, Schned AR, Noelle RJ, Burns CM.
    Arthritis Rheum; 2003 Sep 15; 48(9):2541-54. PubMed ID: 13130474
    [Abstract] [Full Text] [Related]

  • 51. Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide.
    Marino M, Ruvo M, De Falco S, Fassina G.
    Nat Biotechnol; 2000 Jul 15; 18(7):735-9. PubMed ID: 10888840
    [Abstract] [Full Text] [Related]

  • 52. Suppression of systemic lupus erythematosus disease in mice by oral administration of kidney extract.
    Ofosu-Appiah W, Sfeir G, Viti D, Burashnikova E.
    J Autoimmun; 1999 Dec 15; 13(4):405-14. PubMed ID: 10585756
    [Abstract] [Full Text] [Related]

  • 53. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.
    Borel P, Benkhoucha M, Weber MS, Zamvil SS, Santiago-Raber ML, Lalive PH.
    Int Immunol; 2008 Oct 15; 20(10):1313-9. PubMed ID: 18687587
    [Abstract] [Full Text] [Related]

  • 54. Prevention and reversal of lupus in NZB/NZW mice by costimulatory blockade with adeno-associated virus-mediated gene transfer.
    Ye X, Zhu T, Bastacky S, McHale T, Li J, Xiao X.
    Arthritis Rheum; 2005 Dec 15; 52(12):3975-86. PubMed ID: 16329128
    [Abstract] [Full Text] [Related]

  • 55. Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice.
    Patole PS, Pawar RD, Lech M, Zecher D, Schmidt H, Segerer S, Ellwart A, Henger A, Kretzler M, Anders HJ.
    Nephrol Dial Transplant; 2006 Nov 15; 21(11):3062-73. PubMed ID: 16954173
    [Abstract] [Full Text] [Related]

  • 56. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus.
    Jimenez-Caliani AJ, Jimenez-Jorge S, Molinero P, Rubio A, Guerrero JM, Osuna C.
    J Pineal Res; 2008 Sep 15; 45(2):204-11. PubMed ID: 18507713
    [Abstract] [Full Text] [Related]

  • 57. Systemic autoimmune disease induced by dendritic cells that have captured necrotic but not apoptotic cells in susceptible mouse strains.
    Ma L, Chan KW, Trendell-Smith NJ, Wu A, Tian L, Lam AC, Chan AK, Lo CK, Chik S, Ko KH, To CK, Kam SK, Li XS, Yang CH, Leung SY, Ng MH, Stott DI, MacPherson GG, Huang FP.
    Eur J Immunol; 2005 Nov 15; 35(11):3364-75. PubMed ID: 16224814
    [Abstract] [Full Text] [Related]

  • 58. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist.
    Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ.
    Eur J Immunol; 2005 Aug 15; 35(8):2496-506. PubMed ID: 16052609
    [Abstract] [Full Text] [Related]

  • 59. Induction of systemic lupus erythematosus syndrome in BALB/c mice by immunization with active chromatin.
    Li H, Zhang YY, Sun YN, Huang XY, Jia YF, Li D.
    Acta Pharmacol Sin; 2004 Jun 15; 25(6):807-11. PubMed ID: 15169636
    [Abstract] [Full Text] [Related]

  • 60. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A, Hall SR, Körner M, Herrmann M, Schmid RA, Frese S.
    Arthritis Res Ther; 2016 Oct 22; 18(1):243. PubMed ID: 27770825
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.